Several HDAC inhibitors are under clinical development 1; pan-HDAC inhibitors vorinostat and belinostat 3 are also FDA approved in relapsed/refractory CTCL 7 and PTCL 8, respectively. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.